What's Happening?
The University of California San Francisco (UCSF) has commenced a Phase 1 clinical trial to evaluate a wearable ultrasound device designed to silence auditory hallucinations in schizophrenia patients. The trial, named MESSI-LEO (NCT07710989), will test
whether five consecutive daily sessions of low-intensity focused ultrasound (LIFU) targeting the caudate nucleus can reduce or eliminate persistent voices. This deep brain region has been consistently linked to auditory hallucinations that are resistant to conventional medication. The device, ATTN201 by Attune Neurosciences, uses 128 ultrasound transducers to precisely steer sound waves 65 millimeters into the brain. This UCSF trial follows a pilot study that showed over 50% reduction in hallucination severity and frequency in three patients after active LIFU. Concurrently, NYU Langone Health published a study demonstrating that transcranial ultrasound stimulation to the globus pallidus interna reduced delusions in patients with schizophrenia or schizoaffective disorder, further indicating the potential of focused ultrasound in psychiatry.
Why It's Important?
This clinical trial represents a significant advancement in the treatment of medication-resistant schizophrenia, a condition affecting a substantial portion of patients who do not respond to existing pharmacological options. Current antipsychotic drugs often fail to silence hallucinations in up to 40% of patients due to their diffuse action across brain circuits. Clozapine, a more potent drug, offers only partial relief with severe side effects. The wearable ultrasound technology offers a non-invasive method to target specific deep brain structures, like the caudate nucleus, which are inaccessible to other non-pharmacological treatments like transcranial magnetic stimulation (TMS). If successful, this approach could provide a new therapeutic avenue for patients who have endured persistent auditory hallucinations for decades, potentially improving their quality of life and reducing the burden of severe mental illness. The convergence of research from UCSF and NYU Langone Health highlights a growing scientific consensus on the basal ganglia circuitry as a viable therapeutic target for psychosis.
What's Next?
The MESSI-LEO trial will enroll up to 12 participants to primarily establish the safety and feasibility of repeated LIFU sessions. If this Phase 1 trial demonstrates safety and consistent mechanistic and clinical data, the next step would be a larger, double-blind, sham-controlled Phase 2 efficacy trial. This subsequent trial would aim to determine the durability of symptom reductions, optimal treatment parameters (number and interval of sessions), and identify patient populations most likely to respond. Researchers also plan to explore real-time neurophysiological readouts during stimulation, refine individual targeting using connectivity-based biomarkers, and optimize dose-response. The ATTN201 platform is also being investigated in other trials for conditions such as OCD, mild cognitive impairment, drug-resistant epilepsy, depression, and anxiety, building a broader safety database for the technology. The long-term goal is to validate resting-state fMRI connectivity as a quantitative guide for precision psychiatric treatment, allowing for targeted interventions based on individual brain circuit abnormalities.
Beyond the Headlines
The development of wearable focused ultrasound technology for psychiatric conditions could usher in a new era of precision medicine in mental healthcare. Unlike traditional pharmacology, which often involves broad systemic effects, focused ultrasound offers the potential for highly localized neuromodulation, targeting specific brain circuits implicated in symptoms. This approach could lead to treatments with fewer side effects and greater efficacy for conditions that have historically been difficult to manage. Furthermore, the trial implicitly tests the broader scientific question of whether resting-state fMRI connectivity can serve as a reliable imaging-based biomarker for treatment selection and response prediction in psychiatry. If successful, this could transform how psychiatric disorders are diagnosed and treated, moving towards a more objective, data-driven framework. The funding from DARPA, the US Air Force, and US Special Operations Command for cognitive enhancement research using the same platform also hints at broader applications beyond psychiatric treatment, potentially impacting human performance and neurological function in various domains.
